Only 14 pages are availabe for public view
To this day, hepatitis C virus infection represents a global burden. The long term impact of HCV infection is highly variable, ranging from minimal effects to severe extra-hepatic complications.
The goal of therapy is to eradicate HCV and in light of the advances in HCV therapy and treatment, monitoring is required to ensure broad access to these new therapies.
The aim of this study is to investigate possible cardiac effects of direct antiviral drugs “sofosbuvir & daclatasvir” on Egyptian HCV patients.
In this study 60 patients were divided into 2 groups:
group I: IA: Cirrhotic patient received Antiviral drugs without risk factors for cardiac affection
Ib: Cirrhotic patient received Antiviral drugs with risk factors for cardiac affection (as DM, HTN, OBESITY, DYSLIPIDIMIA)
group II: IIA: Non-Cirrhotic patient received Antiviral drugs without risk factors for cardiac affection.
IIB: Non-Cirrhotic patient received Antiviral drugs with risk factors for cardiac affection (as DM, HTN, OBESITY, DYSLIPIDIMIA).
In this study statistical analysis of data showed no changes concerning either laboratory findings ‘liver functions Albumin, Bilirubin, INR & CBC’ or radiological findings ‘by abdominal ultra sound & fibro-scan’ in the study groups after clearing the virus at end of treatment, after 3 months post treatment.
We found that there is cardiac complications i.e.: Electrocardiographic changes happened in the form of bradycardia and first degree heart block for all the participants
And Echocardiographic changes in the form of tricuspid regurgitation, which requires strict monitoring and follow up during treatment and after treatment and to be aware from administrating cardiac medications as ‘amiodarone’ that may lead to drug interactions.